FDA Expands TAVR Indication To Low-Risk Patients
Executive Summary
As expected, the US FDA has expanded the approved indication for four transcatheter aortic valves – Edwards Lifescience’s Sapien 3 and Sapien 3 Ultra, and Medtronic’s CoreValve Evolut R and CoreValve Evolut PRO – to include patients at low risk for complications during surgery.
You may also be interested in...
Cardio Catch-Up: Medtech Innovation Takes Center Stage At TCT 2022
This edition of Medtech Insight’s regular round-up of heart-tech news covers some highlights of this years’ Transcatheter Cardiovascular Therapeutics (TCT) meeting in September, including the latest trials of Abbott's Amulet left-atrial appendage closure device and Medtronic's Intrepid transcatheter mitral valve replacement.
Cardiovascular Catch-Up: Medtronic And Edwards Make Headlines At TCT Conference
The first half of November was full of cardiovascular device news, led by clinical trial results from renal denervation and transcatheter aortic valve trials presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference.
Cardiovascular Catch-Up: J&J RF Balloon Ablation; Biotronik Home Monitor; And More
September has been full of cardiovascular technology news, including announcements from Biotronik and Biosense Webster. Here are a few of the highlights.